Unraveling the nexus: Tumor mutational burden, PD-L1 expression, and oncogenic alterations in non-small cell lung cancer cytology specimens.

Of the 312 cases evaluated, 192 harbored non-small cell lung cancer-specific oncogenic alterations.

Strong positive correlations between tumor mutational burden and PD-L1 were observed in ERBB2-, KRAS-, and BRAF-mutated tumors when evaluated as continuous variables.

TP53 mutations further enhanced immunogenicity when co-occurring with KRAS, ERBB2, or BRAF mutations but this effect was not observed in EGFR-mutated tumors.